Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | GSR | P00390 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686678 | 0.91 | MAPK14 (0.52) | RECQLELANETP53GSRLMNA | |
| SCHEMBL4690782 | 0.91 | RECQL (0.49) | RECQLELANEGSRMAPTLMNA | |
| SCHEMBL4687275 | 0.90 | ELANE (0.52) | RECQLELANETP53GSRMAPT | |
| SCHEMBL4688125 | 0.89 | CCR1 (0.50) | RECQLELANETP53GSRLMNA | |
| SCHEMBL4690237 | 0.89 | GSR (0.49) | RECQLELANETP53GSRLMNA | |
| SCHEMBL4690273 | 0.88 | GSR (0.49) | RECQLELANETP53GSRLMNA | |
| SCHEMBL4690175 | 0.87 | ALDH1A1 (0.48) | RECQLELANETP53GSRPOLB | |
| SCHEMBL4690800 | 0.87 | ELANE (0.65) | ELANEGSR | |
| SCHEMBL4688151 | 0.86 | ELANE (0.47) | RECQLELANETP53GSRABCB1 | |
| SCHEMBL4690475 | 0.86 | SMN1; SMN2 (0.47) | RECQLTP53GSRPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660460-B1 | QUINOXALINE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270666-A1 | Quinoxaline derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| EP-1660460-A1 | QUINOXALINE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021512-A1 | QUINOXALINE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270666-A1 | Quinoxaline derivatives as neutrophil elastase inhibitors and their use | SERPINB1, ELANE, MPO | RECQL 81/4885ELANE 2/4885TP53 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.